Circulating tumor necrosis factor (TNF)-α and soluble TNF-α receptors in patients with Guillain-Barré syndrome11Study supported by a grant from Délégation à la Recherche clinique (AP/HP).

Aderka, 1991, Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients, Cancer Res., 51, 5602 Adolf, 1992, Monoclonal antibodies to soluble human TNF receptor (TNF binding protein) enhance its ability to block TNF toxicity, Cytokine, 4, 180, 10.1016/1043-4666(92)90053-T Asbury, 1969, The inflammatory lesion in idiopathic neuritis - Its role in pathogenesis, Medicine, 48, 173, 10.1097/00005792-196905000-00001 Asbury, 1978, Criteria for diagnosis of Guillain-Barré syndrome, Ann. Neurol., 3, 565 Bansil, 1991, Clinical correlation with serum-soluble interleukin-2 receptor levels in Guillain-Barré syndrome, Neurology, 41, 1302, 10.1212/WNL.41.8.1302 Beutler, 1985, Cachectin/tumor necrosis factor: Production, distribution, and metabolic fate in vivo, J. Immunol., 135, 3972, 10.4049/jimmunol.135.6.3972 Cottrell, 1992, Cytokine kinetics in septic ARF patients on continuous veno-veno hemodialysis (CVVHD), J. Am. Soc. Nephrol., 3, 361 Drapkin, 1989, Plasmapheresis for fulminant meningococcemia, Ped. Infect. Dis. J., 8, 399, 10.1097/00006454-198906000-00015 Engelmann, 1989, A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity, J. Biol. Chem., 264, 11974, 10.1016/S0021-9258(18)80162-4 Exley, 1994, Tumour necrosis factor-α and other cytokines in Guillain-Barré syndrome, J. Neurol. Neurosurg. Psychiatry, 57, 1118, 10.1136/jnnp.57.9.1118 Gherardi, 1994, Early weight loss and high serum tumor necrosis factor-a levels in polyneuropathy, organomegaly, endocrinopathy, M protein, skin changes syndrome, Ann. Neurol., 35, 501, 10.1002/ana.410350423 Girardin, 1992, Imbalance between tumor necrosis factor α and soluble TNF receptor concentrations in severe meningococcemia, Immunology, 76, 20 Griffin, 1993, Macrophage systems in peripheral nerves. A review, J. Neuropathol. Exp. Neurol., 52, 553, 10.1097/00005072-199311000-00001 Hartung, 1990, T cell activation in Guillain-Barré syndrome and in MS: Elevated serum levels of soluble IL-2 receptors, Neurology, 40, 215, 10.1212/WNL.40.2.215 Hartung, 1991, Serum interleukin-2 concentrations in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuroapthy: Comparison with other neurological diseases of presumed immunopathogenesis, Ann. Neurol., 30, 48, 10.1002/ana.410300110 Iqbal, 1981, Cell mediated immunity in idiopathic polyneuritis, Ann. Neurol., 9, 65, 10.1002/ana.410090711 Jacobs, 1993, Pharmacokinetic parameters and biodistribution of soluble cytokine receptors, Int. Rev. Exp. Pathol., 34B, 123, 10.1016/B978-0-12-364935-5.50013-4 Koski, 1986, Clinical correlation with anti-peripheral-nerve myelin antibodies in Guillain-Barré syndrome, Ann. Neurol., 19, 573, 10.1002/ana.410190609 Langkopf, 1994, Soluble tumour necrosis factor receptors as prognostic factors in cancer patients, Lancet, 344, 57, 10.1016/S0140-6736(94)91078-2 Lantz, 1990, Infusion of tumor necrosis factor TNF causes an increase in circulating TNF-binding proteins in humans, Cytokine, 2, 402, 10.1016/1043-4666(90)90048-X Maimone, 1993, Interleukin-6 levels in the cerebrospinal fluid and serum of patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy, J. Neuroimmunol., 47, 55, 10.1016/0165-5728(93)90284-6 Moldawer, 1993, Interleukin-1, TNFα and their naturally occurring antagonists in sepsis, Blood Purif., 11, 128, 10.1159/000170106 Molher, 1993, Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists, J. Immunol., 151, 1548, 10.4049/jimmunol.151.3.1548 Olsson, 1989, Isolation and characterization of a tumor necrosis factor binding protein from urine, Eur. J. Haematol., 42, 270, 10.1111/j.1600-0609.1989.tb00111.x Pereira, 1994, Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients, Kidney Int., 45, 890, 10.1038/ki.1994.117 Redford, 1995, Vascular changes and demyelination induced by the intraneural injection of tumour necrosis factor, Brain, 118, 869, 10.1093/brain/118.4.869 Rieckmann, 1994, Serial analysis of circulating adhesion molecules and TNF receptor in serum from patients with multiple sclerosis: cICAM-1 is an indicator for relapse, Neurology, 44, 2367, 10.1212/WNL.44.12.2367 Saïd, 1992, Nerve lesions induced by macrophage activation, Res. Immunol., 143, 589, 10.1016/0923-2494(92)80040-R Seckinger, 1992, Natural inhibitors of TNF, Immunol. Ser., 56, 217 Seckinger, 1989, Purification and biologic characterization of a specific tumor necrosis alpha inhibitor, J. Biol. Chem., 264, 11966, 10.1016/S0021-9258(18)80161-2 Selmaj, 1988, Tumor necrosis factor mediates myelin and oligodendrocytes damage in vitro, Ann. Neurol., 23, 339, 10.1002/ana.410230405 Selmaj, 1991, Anti-tumor necrosis factor therapy abrogates autoimmune demyelination, Ann. Neurol., 30, 694, 10.1002/ana.410300510 Sharief, 1993, Elevated serum levels of tumor necrosis factor-α in Guillain-Barré syndrome, Ann. Neurol., 33, 591, 10.1002/ana.410330606 Spinas, 1992, Release of soluble receptor for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxemia, J. Clin. Invest., 90, 533, 10.1172/JCI115891 Taylor, 1989, T lymphocyte activation antigens in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy, J. Neurol. Sci., 24, 33 Tsukada, 1991, Tumor necrosis factor and interleukin-1 in the CSF and sera of patients with multiple sclerosis, J. Neurol. Sci., 102, 230, 10.1016/0022-510X(91)90315-X Villard, 1993, Could natural inhibitors of tumor necrosis factor-α modify the clinical course of fulminant meningococcemia, Crit. Care Med., 21, 1396, 10.1097/00003246-199309000-00025 Ythier, 1993, Protective effect of natural TNF-binding protein on human TNF-induced toxicity in mice, Cytokine, 5, 459, 10.1016/1043-4666(93)90036-5